[Effects of beraprost sodium (a PGI2 derivative) on chronic hypoxic pulmonary hypertension in the rat].
To determine whether beraprost sodium (beraprost) can cause pulmonary vasodilation in chronic hypoxic pulmonary hypertension, we measured the hemodynamic effects of intravenous beraprost, a stable and orally active agent with a PGI2-like structure, in chronic hypoxic (H) and normoxic (N) rats. During anesthesia baseline pulmonary artery pressure (PAP) was 32.0 +/- 1.0 in H rats and 18.0 +/- 0.4 mmHg in N rats. Intravenous beraprost (20 micrograms/kg) elicited acute pulmonary vasodilation by 17.7 +/- 4.6% (5.6 +/- 1.4 mmHg) in H rats and by 16.8 +/- 2.1% (3.0 +/- 0.6 mmHg) in N rats, which indicates that the relative degree of acute pulmonary vasodilation caused by beraprost was similar in H and N rats. Thirty minutes after the drug was injected, PAP had not returned to baseline levels in either H or N rats, and it was lower in H rats (90 +/- 2%) than in N rats (95 +/- 2%). Lungs were isolated and perfused with saline, and those from H rats and N rats showed similar pulmonary vasodilator responses to 2 and 20 micrograms/kg beraprost. These results indicate that although beraprost caused a similar degree of acute pulmonary vasodilation in H and N rats, in H rats the response lasted longer. Thus PGI2 derivatives may be useful as vasodilators in some patients with primary and secondary pulmonary hypertension.